Elanco Animal Health Inc

Financial performance has remained strong, with revenue growing from $1.03B in Q3 2022 to $1.06B in Q2 2023. Gross profit continued to perform well, with margins at 59% in the latest quarter. Operating income reached $53.00M in Q2 2023, holding a steady 5% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $230.00M. Net income dropped to -$97.00M, keeping EPS at -$0.20. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.